© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Bosentan laid its roots in the search for better ways to manage pulmonary arterial hypertension, a disease that brought high mortality and stifled quality of life. In the early '90s, researchers drilled down into the endothelin pathway, which drives the tight constriction of blood vessels. They homed in on blocking this cascade, and out of many candidates, Bosentan stood out. Its journey to market wasn't just about clever chemistry or luck—years of trials, failures, and patient stories guided its improvement. By the early 2000s, regulatory bodies in Europe and the US cleared Bosentan for clinical use because it showed real improvement in patient exercise capacity and delayed disease progression. Knowing where it came from helps us appreciate both the challenges researchers endure and the hope that medication brings to a community desperate for progress.
Bosentan monohydrate finds its main use as a dual endothelin receptor antagonist. This medicine does more than just hold a spot on pharmacy shelves—its production and consistent quality offer a life line for patients with severe vascular disorders. Drug manufacturers have to meet strict requirements. Not every facility can handle it, because the drug has specific needs around chemical stability and bioavailability. Ultimately, the value of Bosentan comes to life only in the hands of skilled healthcare workers and informed patients.
Bosentan monohydrate lands as an off-white to yellowish crystalline powder. The modifications that bring the monohydrate form—attaching a molecule of water as part of the structure—affect its storage and shelf stability. The compound features a robust sulfonamide linkage, which not only impacts its potency but also presents unique challenges for handling. Its solubility remains moderate in aqueous solutions, and this influences how companies formulate it into tablets. With a molecular weight around 569 g/mol, and a melting point just above 120°C, technicians must control temperature and humidity tightly during any process that involves synthesis or packaging.
Packaged Bosentan products carry labels that do more than offer reassurance—they provide clarity on strength, route of administration, storage, expiration, and excipients. Technicians analyze each batch for purity using tradable metrics like HPLC and NMR, making sure content uniformity meets regulatory standards. The tablets or powder forms arrive stamped with unique batch numbers and safety statements. Coming from my own time observing quality assurance teams, nobody treats this like a checklist; everyone in the plant knows that a single missing warning or mislabel could endanger a patient. Checking and documenting gets top billing through every shift.
Making Bosentan follows a multi-step synthetic route. Chemists start with a biphenyl base and build up through nitration, reduction, sulfonation, and coupling reactions. Each transformation introduces the necessary functional groups for blocking endothelin receptors. Synthesis demands clean solvents, and each batch passes through several stages of purification, including crystallization and filtration. Critical to success, teams control the reaction environment, watching temperature, pH, and pressure all the way. The monohydrate step requires precise water addition, and if technicians miss their window, product stability drops. The difficulties don’t stop in the lab—scaling to commercial production can introduce new impurities and troubleshooting never fully ends.
The core chemical challenge inside Bosentan involves assembling and protecting reactive groups throughout esterification, sulfonation, and hydrogenation reactions. Each step invites risk—too much acid or base, and key intermediates degrade. Process chemists sometimes introduce alternative solvents or hybrid catalysts to reduce unwanted byproducts. Over years, documented tweaks to these steps improved yields and lowered waste outputs. Scientists also studied salt forms and particle sizes to tweak absorption in the human body. That’s how the monohydrate form found its benefits, including easier handling and better shelf life compared to the anhydrous base.
Bosentan answers to a range of names across literature and the marketplace. When reading research or recalls, you’ll spot names like Ro 47-0203, Tracleer, and systematic tags like 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzenesulfonamide monohydrate. Each name ties to unique stages in development—clinical trials, patent filings, or branding for prescription use. Any confusion here causes delays or worse, so clear cross-referencing smooths operation for researchers, doctors, and patients alike.
Running a Bosentan manufacturing line or clinical site comes with real risk, not just to patients but to staff in the plant or pharmacy windows. The compound’s toxicity profile means anyone exposed requires gloves, eye protection, and access to exhaust hoods. Workers must keep Bosentan off skin and avoid inhaling dust. Companies train all new staff on spill cleanup, and safety officers run drills on exposure response. Storage vaults need low humidity and proper temperature control, because heat or water vapor can degrade the batch long before its expiration. Close documentation tracks every dose from barrel to finished box, and inspectors have open access to review practices at any moment.
Doctors use Bosentan monohydrate to treat pulmonary arterial hypertension. The drug expands blood vessels, lowers blood pressure in the lungs, and slows down right heart failure. For certain types of systemic sclerosis, Bosentan makes a difference in combating digital ulcers. Its oral tablet form gives patients a measure of independence. Over the years I’ve seen pulmonologists debate dose adjustments, considering the drug’s load on the liver and interaction with other treatments. In low-resource settings, access to Bosentan can remain limited, so push for generic formulations and broader registration across countries matters a great deal. The applications continue to grow as clinical trials expand to other vascular and fibrotic diseases, showing the reach of research long after market launch.
Bosentan’s story didn’t end with its first market approval. Researchers keep searching for improved receptor selectivity, longer half-lives, and tablet forms that work better for older adults or those with comorbidities. Recent lab studies pull focus onto the drug’s impact outside lung hypertension—investigations in kidney fibrosis and systemic sclerosis show promise. Universities and pharmaceutical companies collaborate, sharing both raw data and early results at global conferences. Investment dollars flow toward tweaking the synthesis for greener chemistry and lowered production costs. Academics also run registries to collect long-term patient outcomes, which feed back into new studies and safer prescribing.
Bosentan use demands careful watching due to possible liver toxicity, teratogenicity, and interaction with other liver-metabolized drugs. In preclinical animal models, higher doses brought clear patterns of liver enzyme elevation and, in some cases, testicular atrophy. Translation to the clinic means patients get routine liver function tests, and doctors warn women about strict pregnancy prevention steps. Post-marketing surveillance picked up on rare but significant reactions, leading regulatory agencies to add boxed warnings to product labeling. These safety nets result from painstaking research, not guesswork or blanket risk avoidance. Still, ongoing work pushes for biomarkers that would predict rare toxic outcomes, hoping to shield patients who depend on the therapy.
Bosentan’s patent expiration already spawned a wave of generics, which brings needed affordability but also sharp eyes from regulators. With new discoveries in the endothelin pathway, drug makers chase second- or third-generation analogs designed to bind more selectively or avoid hepatic processing altogether. Gene-editing technologies and computational modeling give fresh directions for chemical modification or alternative delivery methods. For patients, hope rests on these advances lowering costs, raising safety, and broadening access beyond specialty centers. As health systems worldwide tighten budgets, Bosentan’s story offers lessons on balancing invention with access and ongoing vigilance in the face of ever-shifting clinical realities.
Bosentan monohydrate plays a big role for people living with certain types of high blood pressure in the lungs, known as pulmonary arterial hypertension (PAH). With PAH, the blood vessels inside the lungs tighten up and make it much harder for the heart to push blood through. Simple things—walking across the room, climbing stairs—can leave folks gasping for air. Bosentan monohydrate, a type of medication called an endothelin receptor antagonist, helps open those blood vessels again, cutting down pressure and lightening the load on the heart.
Doctors have spent years trying to get a handle on pulmonary hypertension because it tends to hit young adults and middle-aged folks, often in the prime of their lives. Before the arrival of drugs like bosentan, options were grim, and people bounced from specialist to specialist just chasing a diagnosis. With bosentan, doctors can offer a legitimate shot at improving someone’s daily life—sometimes even longevity. The medicine works by blocking endothelin, a molecule that squeezes blood vessels way too tight in PAH patients. By keeping endothelin in check, blood moves a little smoother, and the heart doesn’t have to work as hard to force things through.
Plenty of patients describe catching their breath more easily after a few weeks. That’s not just them being optimistic—there’s data behind it. Studies show bosentan can mean less shortness of breath and a better walk distance during a standard six-minute walk test. Some users say they can get through the day without needing to stop and catch their breath as much as before. Hospital stays go down because the right medication keeps breathing crises in check. That kind of progress means less time spent panicking, more time spent living.
Like most powerful medicines, bosentan doesn’t come without baggage. People taking it have to go in for regular blood tests to check on their liver, because the medicine can put some strain on it. Swelling, headaches, and changes in blood numbers are common enough to need a close watch. For women, questions about pregnancy enter the mix—the drug can cause harm to an unborn baby, so birth control and doctor visits land high on the list.
One tough part about living with a rare lung condition: not everyone gets a clear path to care. PAH often looks like asthma or chronic fatigue before anyone figures out what’s really wrong. That means people can go untreated or even get the wrong kind of help. Primary care doctors, lung specialists, and pharmacists who recognize the early signs can shorten the time to proper treatment with bosentan. Spreading the word about PAH plays a real part in catching these cases early. The science keeps moving forward, but a little more awareness—alongside new treatments—helps folks get back on their feet sooner.
Having watched loved ones struggle with chronic lung diseases, it hits close to home to see a medication offer a pathway to more active days. Real quality of life comes from not being held hostage by breathlessness. Bosentan monohydrate sits on the front line for many living with harsh lung conditions, giving them a fighting chance to turn medical hope into something you can feel day by day.
Doctors turn to Bosentan Monohydrate most often for people struggling with pulmonary arterial hypertension. Folks on this medication face some tough trade-offs—not just the hope of better breathing, but the challenge of handling side effects that come along for the ride. For many, those unwanted effects go beyond simple discomfort and start to affect daily routines.
When it comes to liver issues, there’s no skirting around the risks. Bosentan’s track record with liver enzymes tells a clear story. Nearly one out of every ten people on the drug sees higher liver enzyme levels. The body doesn’t give much warning before problems start. A person might feel nothing at first, but a blood test picks it up. If yellowing of the skin or eyes shows up, fatigue sets in, or urine darkens, those are strong signals to check in with a medical team right away. Some people experience a need to cut back their dosage or stop using Bosentan entirely if the liver shows signs it’s struggling.
Swelling in the ankles, feet, or lower legs—doctors call it edema—often appears around the time Bosentan starts working in the system. People may need bigger shoes, rings won’t fit, or pants start feeling too snug. It can be discouraging. The body holds on to salt and water, especially for those already dealing with heart or kidney issues. Tracking daily weight and watching for tightness in clothing can give early clues so it doesn’t sneak up on you.
Headaches strike a lot of people early in treatment. Some say it feels like having a head cold—the sinuses clog, making sleep tough and mornings even tougher. Many rely on non-prescription remedies, but not every fix is safe, especially with the heart in play. Checking with a doctor first helps keep side effects from snowballing.
Bosentan drops the red blood cell count in some folks. People feel a lack of energy, get winded climbing stairs, or need more breaks. Doctors call it anemia. Mild cases get by with extra rest and iron in the diet. Sometimes blood tests push for more aggressive help. Sticking to follow-up visits helps flag problems sooner instead of letting the situation drain energy and mood.
This part’s tough to talk about but matters most—Bosentan carries a strong warning about causing birth defects. Women of childbearing age need two forms of birth control, and regular pregnancy tests are a must. There’s no shortcut, no safe way to take risks here. This isn’t just some rare concern; the danger ranks right up there with liver injury as the biggest reason doctors stay hands-on with their patients.
Experiences with Bosentan Monohydrate teach us—side effects show up in the lab work as often as in daily aches. Catching issues early comes down to staying connected with a reliable medical team and owning your own lab and symptom tracking. Support from family and friends helps too. Taking this kind of medicine calls for more than a pillbox; it needs vigilance and honest conversations with healthcare providers.
Bosentan Monohydrate is no stranger to people dealing with pulmonary arterial hypertension (PAH). This medicine doesn’t pretend to cure, but it can help ease the strain that comes with PAH. Doctors use it to relax blood vessels, letting blood move with less resistance. There’s science behind that: Bosentan blocks certain chemicals in the body that narrow vessels in the lungs. By opening things up, it makes it less work for the heart to pump blood. People living with this condition know how much difference that can make for day-to-day life.
Most folks get their Bosentan as a tablet. Swallow it with water — that’s the usual route. Some try to crush their tablets to make swallowing easier, especially if they have trouble with pills. Doctors usually advise against breaking tablets unless there’s a particular reason and a clear okay. Why? Each tablet is formulated for the right release in the gut, so crushing could send too much medicine into the body at once, or not enough.
Timing matters. Bosentan should be taken twice a day, roughly 12 hours apart, with or without food. Real life doesn’t revolve around the clock, but keeping doses roughly the same time each morning and night helps the body stay in a good rhythm. Consistency helps keep levels steady in your system, which is what you’re after if you want the benefits.
Bosentan can impact the liver. People starting this medication get regular blood tests to keep tabs on their liver function, especially in the early weeks. I remember talking with a friend who started Bosentan and got worried about the extra trips for bloodwork. She told me, “It felt annoying at first, but later I saw how it caught some minor liver changes before they turned serious.” It’s not just about playing it safe — keeping track like that reduces the odds of bigger issues later on.
Bosentan can cause serious harm if taken during pregnancy. For women who could become pregnant, the rules are clear: use reliable birth control, and check in with the doctor regularly to confirm everything is on track. There’s no wiggle room here. No one wants to take risks with a developing baby, so it’s normal for clinics to ask for proof of negative pregnancy tests before handing over this medication. This isn’t just red tape. Birth defects are real, and doctors have seen them happen when guidelines aren’t followed.
This medicine doesn’t play nice in every situation. Other meds, like certain HIV medicines or birth control pills, can mix badly with Bosentan. Even grapefruit juice can change how the drug works in the body. I once saw a relative’s medication plan completely reshuffled because the specialist caught a combination that would have done more harm than good. Honest chat with the doctor about every vitamin, supplement, or remedy going down is the best way to avoid surprises.
Missing doses happens. Life gets busy. But skipping medicine too often weakens its benefit. People find that setting phone alarms or using pillboxes helps. Some clinics offer reminders or apps that help people stick to routines. Health isn’t just about the science — it’s about practical ways folks can fit medicines into messy, unpredictable days.
Bosentan monohydrate sits in the treatment plans for people living with pulmonary arterial hypertension. This medicine has brought relief to those struggling with stubborn symptoms, but anyone using it—or caring for someone who does—has to keep their eyes open for possible drug interactions.
After years of sifting through medical information for my own family and in my professional work, the value of understanding your medications can’t be overstated. Blood pressure changes, liver enzymes, and even birth control might all get tangled up once bosentan enters the picture.
Bosentan acts mainly as an endothelin receptor antagonist, but what matters most for doctors and patients is how it revs up certain liver enzymes called CYP3A4 and CYP2C9. This means it can push other medicines through the body faster, or they can do the same to bosentan, throwing off the careful balance required for effective treatment.
I’ve watched friends deal with side effects from unsuspected medication cross-talk, sometimes because they added something as simple as an antifungal pill or changed their cholesterol prescription. With bosentan, rifampin, a common antibiotic, can bump its levels up, boosting risks for dangerous side effects. On the flip side, ketoconazole lowers how quickly bosentan is broken down, meaning the drug sticks around longer and can stress the liver. Oral contraceptives, which many folks rely on to prevent pregnancy, can actually drop in effectiveness, because bosentan messes with their cycle in the liver. That’s not a minor concern for patients who need that coverage.
Pharmacists have flagged statins, warfarin, and glyburide as troublemakers alongside bosentan. Not just because of rare complications, but because these drugs regularly pop up in people’s medicine cabinets. Diabetes, cholesterol, heart problems—many people facing pulmonary arterial hypertension already manage several conditions. Combining those pills with bosentan means risking unplanned dips or spikes in their effectiveness.
Nobody wants to end up with an unexpected hospital trip because their blood thinner got wiped out by a new prescription. The challenge for doctors is balancing bosentan’s benefits with the reality of modern, multi-drug medical care, where every pill added or removed changes the game.
Doctors and patients can do more than just keep an updated pill list. Frequent blood tests to check liver enzymes, talking honestly about over-the-counter supplements and new prescriptions, and looping pharmacists into these conversations all help keep interactions in check. Open communication let me catch a problem once after an elderly friend’s medication list changed—nobody had double-checked how all her medications combined. These small steps kept her out of trouble and caught the downward spiral long before it affected her health.
Staying safe with bosentan doesn’t just mean trusting a label or a leaflet. It means committing to regular check-ins with your healthcare team, sharing full information, and understanding that every medicine enters an already-busy system with presets and priorities. The more everyone knows about these drug combinations, the more likely they are to spot, prevent, and solve problems before they escalate.
Mixing bosentan with other medications brings real risks that reach beyond one specialty or diagnosis. People who have seen the consequences of missed interactions know the difference preparation can make. Checking, double-checking, and having honest discussions turns a complicated therapy plan into a safer, more predictable journey.
Bosentan monohydrate helps manage pulmonary arterial hypertension, a serious condition that causes high blood pressure in the blood vessels connecting heart and lungs. Drug companies developed it as an endothelin receptor antagonist, hoping to give people a better quality of life. Doctors understand the benefits, but they also know this medicine has some tough side effects, especially for women who are or might become pregnant.
Researchers studying Bosentan found it crosses the placenta. Animal studies raised alarms early on; pregnant rats and rabbits developed birth defects after getting doses much lower than those given to humans. Some of these defects affected the face, already a sign that this class of drugs could seriously interfere with fetal development.
Drug regulators, including those in the US and Europe, quickly issued warnings about the use of Bosentan among women who could become pregnant. The FDA labeled it as Pregnancy Category X. This means if a woman is pregnant or planning to be, doctors advise against using it. Still, pulmonary arterial hypertension in pregnancy can be deadly, and treatment sometimes becomes about weighing life-and-death risks for the mother against those for the fetus.
Doctors regularly tell women taking Bosentan to use reliable birth control. Written documentation and pregnancy tests form part of the process, not just background paperwork. Physicians don’t like forcing tough calls, but there aren’t many good alternatives for serious pulmonary hypertension, so counseling and full disclosure become key. In my experience working in health settings, the stress on both the patient and medical staff ramps up in these situations—nobody wants to take even tiny risks when a baby is involved.
Pharmacists get involved with educational counseling, making sure every woman understands the risk since Bosentan doesn’t just have an unlikely risk: the known science shows there’s real harm to a fetus. Real-world drug registries echo the animal studies—cases of malformation and miscarriage are more frequent than in the general population. There’s no sugar-coating this drug’s label.
Doctors sometimes explore older medications that seem milder during pregnancy, such as certain calcium channel blockers or prostacyclins, yet the data on safety remain limited. Managing a mother’s heart and lungs sometimes requires careful collaboration between heart specialists and high-risk pregnancy doctors, and the results can be unpredictable. For some women, the right thing means staying off Bosentan and compensating with other medicines and close monitoring.
Better research into pregnancy-safe alternatives stands out as a top need. Drug companies need to speed up development and testing of safer options. Advocacy groups urge more registries to track real-world outcomes in both mothers and babies. Improved early diagnosis of pulmonary hypertension could prevent emergencies during pregnancy in the first place.
Health systems don’t just keep this information between doctors and pharmacists. Every woman prescribed Bosentan in her childbearing years deserves a straight conversation about the risks, strong support in preventing pregnancy if she chooses, and help figuring out her options if pregnancy does occur. Transparency, early intervention, and a willingness to look for different solutions give families the best shot at healthy outcomes.
| Names | |
| Preferred IUPAC name | 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)benzothiazol-7-yl]benzenesulfonamide monohydrate |
| Other names |
Bosentan hydrate Tracleer monohydrate RO 47-0203 monohydrate Bis(4-(2-hydroxyethyl)-1,3-thiazol-2-yl)diazene-1,2-diyl]bis[methanesulfonamide] monohydrate |
| Pronunciation | /boʊˈsɛntæn ˌmɒn.oʊˈhaɪ.dreɪt/ |
| Identifiers | |
| CAS Number | 153559-49-0 |
| Beilstein Reference | 3688604 |
| ChEBI | CHEBI:63599 |
| ChEMBL | CHEMBL1201735 |
| ChemSpider | 3563198 |
| DrugBank | DB00620 |
| ECHA InfoCard | echa-InfoCard-100004579706 |
| EC Number | EC 603-942-2 |
| Gmelin Reference | 8201437 |
| KEGG | D08914 |
| MeSH | D000072371 |
| PubChem CID | 102185876 |
| RTECS number | GNK7I56VV4 |
| UNII | BEU1B01UUX |
| UN number | UN3462 |
| Properties | |
| Chemical formula | C27H29N5O6S·H2O |
| Molar mass | 569.65 g/mol |
| Appearance | white to off-white powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 2.64 |
| Vapor pressure | <0.00001 mmHg at 25°C (estimated) |
| Acidity (pKa) | 4.6 |
| Basicity (pKb) | 6.33 |
| Magnetic susceptibility (χ) | -7.4e-6 |
| Dipole moment | 3.2 ± 0.5 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 248.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | 0 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | Std enthalpy of combustion (ΔcH⦵298) of Bosentan Monohydrate: "-9730 kJ/mol |
| Pharmacology | |
| ATC code | C02KX01 |
| Hazards | |
| Main hazards | May damage the unborn child. Suspected of damaging fertility. May cause harm to breast-fed children. Causes serious eye irritation. May cause cancer. |
| GHS labelling | GHS05, GHS07, GHS08 |
| Pictograms | GHS08,GHS07 |
| Signal word | Danger |
| Hazard statements | Hazard statements: H360, H362 |
| Precautionary statements | P264, P270, P273, P280, P301+P312, P302+P352, P305+P351+P338, P308+P313, P337+P313, P501 |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Flash point | > 250 °C |
| Lethal dose or concentration | LD50 Oral Rat 1,455 mg/kg |
| LD50 (median dose) | LD50 (median dose): Rat oral LD50 = 2,292 mg/kg |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Bosentan Monohydrate: Not established |
| REL (Recommended) | 100 mg daily |
| Related compounds | |
| Related compounds |
Bosentan Macitentan Ambrisentan Sitaxentan Darusentan Sodium Bosentan |
